March 24, 2026 · /semaglutide · 15 min read

Semaglutide Dosage Guide: How Much to Take, How Often, and For How Long (2026)

Founder & Lead Researcher

Reviewed by Peptide Nerds Editorial · Updated April 2026

Important: We are not doctors. Everything in this article is based on published research and publicly available clinical data. It is not medical advice. Talk to your physician before changing any medication or health protocol.

Semaglutide Dosage for Weight Loss: How Much, How Often, and For How Long

The FDA-approved dose of semaglutide for weight loss is 2.4 mg once weekly, delivered as a subcutaneous injection. In the STEP 1 trial, researchers administered this dose over 68 weeks and saw an average body weight reduction of 14.9% (Wilding et al., 2021).

New to semaglutide? Our interactive dosage guide tells you exactly what to buy, how to mix, and how many syringe units to draw each week.

As of March 19, 2026, there is a new option. The FDA approved Wegovy HD at 7.2 mg once weekly. In the STEP UP trial, this higher dose produced 20.7% mean weight loss at 72 weeks, with roughly one in three participants losing 25% or more of their body weight.

But you do not start at 2.4 mg. And you definitely do not start at 7.2 mg. The titration schedule matters more than the final number on the label. Here is what the clinical data actually shows, step by step.

The Bottom Line

Semaglutide is the drug inside Ozempic and Wegovy. It is a GLP-1 receptor agonist, which means it mimics a gut hormone that controls hunger and blood sugar.
You start at a tiny dose (0.25 mg per week) and slowly work up over 4-5 months. The standard maintenance dose is 2.4 mg once per week. A new higher dose of 7.2 mg was approved in March 2026.
Do not rush it. The slow ramp-up exists to reduce nausea and stomach issues. Skipping steps leads to worse side effects and more people quitting.
In clinical trials, the 2.4 mg dose produced about 15% body weight loss over 68 weeks. The 7.2 mg dose produced about 21% over 72 weeks. Results take months, not days.
When people stopped taking it, they regained about two-thirds of the weight within a year. This is a long-term medication for most people, not a short course.
Your doctor should manage your dosing. Do not adjust the dose or schedule on your own.

Key Takeaways

The standard semaglutide titration starts at 0.25 mg weekly and increases every 4 weeks to a maintenance dose of 2.4 mg over 16-20 weeks (Wilding et al., 2021)
The new 7.2 mg high dose (Wegovy HD) was FDA-approved March 19, 2026, and produced 20.7% mean weight loss at 72 weeks in the STEP UP trial
In the STEP 1 trial, 86.4% of participants on 2.4 mg lost at least 5% of their body weight, and 50.5% lost 15% or more
Gastrointestinal side effects (nausea, diarrhea, vomiting) are the most common and are dose-dependent. Starting low reduces them significantly.
One year after stopping semaglutide, participants regained about two-thirds of the weight they had lost (Wilding et al., 2022)
Semaglutide is FDA-approved for chronic weight management at 2.4 mg (Wegovy) and 7.2 mg (Wegovy HD). Talk to your physician about which dose is right for you.

What the Clinical Trials Used

Semaglutide Dosage Chart

Phase	Dose	Frequency	Duration	Source
Starting	0.25 mg	Once weekly	Weeks 1-4	STEP 1, PMID: 33567185
Titration 1	0.5 mg	Once weekly	Weeks 5-8	STEP 1, PMID: 33567185
Titration 2	1.0 mg	Once weekly	Weeks 9-12	STEP 1, PMID: 33567185
Titration 3	1.7 mg	Once weekly	Weeks 13-16	STEP 1, PMID: 33567185
Maintenance	2.4 mg	Once weekly	Week 17+	STEP 1, PMID: 33567185

For the new high-dose pathway (Wegovy HD), the titration continues beyond 2.4 mg:

Phase	Dose	Frequency	Duration	Source
Titration 4	3.6 mg	Once weekly	4 weeks	STEP UP trial
Titration 5	5.4 mg	Once weekly	4 weeks	STEP UP trial
High-Dose Maintenance	7.2 mg	Once weekly	Ongoing	STEP UP trial

The total titration from 0.25 mg to 7.2 mg takes approximately 28 weeks.

Why the Titration Matters

Starting at the full dose would be a bad time. In the STEP 1 trial, even with the slow titration schedule, 44.2% of participants on semaglutide reported nausea at some point during the study. The titration exists to let your GI system adjust.

The 4-week steps give the body time to adapt to each dose level before moving up. Most nausea and GI symptoms peak in the first few days after a dose increase and fade within 1-2 weeks. Researchers found that skipping or rushing the titration led to higher rates of discontinuation.

In the STEP 1 trial, only 4.5% of semaglutide participants discontinued due to GI side effects. That is a low dropout rate for a drug that causes nausea in nearly half of users. The titration schedule is the reason. Talk to your physician before adjusting the pace of titration in either direction.

Dose-Response: More Is Not Always Better

The clinical data shows a clear relationship between dose and weight loss. But the curve flattens as doses get higher. Here is what the trials showed.

Dose	Weight Loss (%)	Trial	Duration	Population
1.0 mg	-6.9%	STEP 2, PMID: 33667417	68 weeks	Overweight/obese with T2D
2.4 mg	-9.6%	STEP 2, PMID: 33667417	68 weeks	Overweight/obese with T2D
2.4 mg	-14.9%	STEP 1, PMID: 33567185	68 weeks	Overweight/obese without diabetes
7.2 mg	-20.7%	STEP UP	72 weeks	Overweight/obese without diabetes

Two things stand out. First, type 2 diabetes blunts the weight loss response. The same 2.4 mg dose produced 14.9% loss in people without diabetes but only 9.6% in people with it. Second, the jump from 2.4 mg to 7.2 mg (tripling the dose) added roughly 6 percentage points of weight loss. That is meaningful, but not triple the results.

For many people, 2.4 mg may be sufficient. The decision to titrate higher should be made with a physician based on individual response and tolerability.

How Long to Take It

What the Studies Show

The major semaglutide trials ran 68-72 weeks. The STEP 1 trial ran 68 weeks. The STEP UP trial ran 72 weeks. In both cases, weight loss continued throughout the study period, though the rate of loss slowed after the first 6 months.

Most participants reached roughly 80% of their total weight loss by week 40. The remaining 20% came over the next 28-32 weeks. This matters because people who expect dramatic ongoing losses after the first few months may feel like the drug "stopped working." It did not. The rate simply slows as you weigh less and your body reaches a new equilibrium.

What Happens When You Stop

This is the data most people do not want to hear. In the STEP 1 trial extension, researchers followed participants for one year after they stopped semaglutide. The results were clear.

Participants who had lost an average of 17.3% of their body weight on semaglutide regained about two-thirds of that loss within one year of stopping. Their net weight loss at week 120 (52 weeks after stopping) was only 5.6% from baseline (Wilding et al., 2022).

Cardiometabolic improvements (blood pressure, cholesterol, blood sugar) also reverted toward baseline after stopping.

This does not mean semaglutide is a failure. It means obesity is a chronic condition that usually requires ongoing treatment. The same is true for blood pressure medications and statins. Talk to your physician about long-term treatment planning.

Cycling Protocols

Semaglutide is not typically cycled. Unlike research peptides that may benefit from on/off periods, GLP-1 receptor agonists are designed for continuous use under medical supervision.

The STEP 1 extension data makes this clear. Stopping leads to weight regain. There is no published evidence supporting a cycling protocol for semaglutide.

Some physicians use a dose reduction approach instead, lowering from 2.4 mg to 1.7 mg or 1.0 mg for long-term maintenance after a patient reaches their goal. This is a clinical decision, not something to do on your own.

Side Effects by Dose

Side Effect	1.0 mg	2.4 mg	7.2 mg	Source
Nausea	~30%	~44%	Higher (dose-dependent)	STEP 1 / STEP 2 / STEP UP
Diarrhea	~20%	~30%	Higher (dose-dependent)	STEP 1 / STEP 2 / STEP UP
Vomiting	~10%	~24%	Higher (dose-dependent)	STEP 1 / STEP 2 / STEP UP
Constipation	~16%	~24%	Higher (dose-dependent)	STEP 1 / STEP 2 / STEP UP
Dysesthesia (tingling/numbness)	Low	~4.9%	~18.9%	STEP UP / STEP UP T2D
Discontinuation due to GI events	~2%	~4.5%	Higher	STEP 1 / STEP UP

Dysesthesia is the new signal to watch. In the STEP UP T2D trial, 18.9% of participants on the 7.2 mg dose reported tingling or numbness, compared to 4.9% on 2.4 mg and 0% on placebo. This is a notable safety finding that was not seen at lower doses.

Managing Side Effects

Eating smaller meals helps. High-fat and fried foods tend to make nausea worse during the first few weeks of each dose increase. Most clinical guidance recommends eating slowly, stopping when full, and avoiding foods that trigger nausea.

Staying hydrated matters, especially if diarrhea or vomiting occurs. Dehydration can compound the GI symptoms.

Most side effects are transient. In the STEP 1 trial, GI symptoms were described as "mild to moderate" and "subsided with time" for the majority of participants. If symptoms persist or become severe, that is a signal to talk to your physician about dose adjustment.

How Semaglutide Compares

Compound	Starting Dose	Max Dose	Frequency	Weight Loss (Max Dose)	Trial	Status
Semaglutide (Wegovy)	0.25 mg	2.4 mg	Once weekly	-14.9% at 68 wks	STEP 1	FDA-approved
Semaglutide (Wegovy HD)	0.25 mg	7.2 mg	Once weekly	-20.7% at 72 wks	STEP UP	FDA-approved (March 2026)
Tirzepatide (Zepbound)	2.5 mg	15 mg	Once weekly	-20.9% at 72 wks	SURMOUNT-1	FDA-approved
Retatrutide	1 mg	12 mg	Once weekly	-24.2% at 48 wks	Phase 2	Investigational

Tirzepatide is a dual GLP-1/GIP receptor agonist. At its highest dose (15 mg), it produced nearly identical weight loss to the new semaglutide 7.2 mg dose, though in a 72-week trial instead of 68 (Jastreboff et al., 2022). The mechanisms differ. Tirzepatide activates two receptors. Semaglutide activates one, but at a higher dose.

Retatrutide is the outlier. As a triple agonist (GLP-1/GIP/glucagon), it produced 24.2% weight loss at only 48 weeks in a Phase 2 trial (Jastreboff et al., 2023). That is a higher percentage in a shorter time frame. But Phase 2 data from 338 participants is not the same as Phase 3 data from thousands. Retatrutide is still investigational and not available by prescription.

For the full comparison, see our semaglutide vs tirzepatide guide.

How to Get Semaglutide Legally

FDA-Approved Options

Semaglutide is FDA-approved under two brand names for two different indications:

Wegovy (0.25 mg to 2.4 mg): Approved for chronic weight management in adults with BMI 30+ (or 27+ with at least one weight-related condition). Also approved for cardiovascular risk reduction.

Wegovy HD (7.2 mg): Approved March 19, 2026, for the same population. Expected to launch in a single-dose pen in April 2026.

Ozempic (0.25 mg to 2.0 mg): Approved for type 2 diabetes. Not approved for weight loss, though it is widely prescribed off-label for this purpose at lower doses.

All require a prescription. Insurance coverage varies. Many commercial plans now cover Wegovy for qualifying patients.

Telehealth Providers

Several telehealth platforms now offer semaglutide prescriptions after a virtual consultation. These typically include an initial assessment, ongoing monitoring, and medication delivery. Look for providers that require lab work and regular check-ins, not just a quick questionnaire.

Compounding Pharmacies

Compounded semaglutide has been available through 503B pharmacies due to ongoing shortages. However, Novo Nordisk has challenged the compounding pathway, and the regulatory status changes frequently. As of March 2026, check the FDA's drug shortage database for the most current information. Any compounded version should come from a licensed 503B pharmacy with third-party testing.

Frequently Asked Questions {#faq}

How much semaglutide should I take for weight loss?

The FDA-approved maintenance dose is 2.4 mg once weekly (Wegovy) or 7.2 mg once weekly (Wegovy HD) for chronic weight management. In the STEP 1 trial, researchers administered 2.4 mg and observed 14.9% mean weight loss. In the STEP UP trial, 7.2 mg produced 20.7% mean weight loss. Both require a slow titration starting at 0.25 mg. Your physician will determine the appropriate dose based on your response and tolerability.

How long does it take for semaglutide to work?

Most participants in the STEP 1 trial saw noticeable weight loss within the first 4-8 weeks, even during the titration phase. The most rapid weight loss occurred between weeks 8 and 28, after reaching the maintenance dose. By week 40, roughly 80% of total weight loss had occurred. Full results in the trials were measured at 68-72 weeks.

Can I take semaglutide every day?

Semaglutide for weight loss (Wegovy) is a once-weekly subcutaneous injection. There is an oral daily formulation (Rybelsus) approved for type 2 diabetes, but it is not approved for weight loss and uses different dosing. Taking the injectable version more frequently than once weekly is not supported by clinical data and increases side effect risk. Talk to your physician about the correct schedule.

What happens if I miss a dose of semaglutide?

According to the prescribing information, if you miss a dose and the next scheduled dose is more than 2 days away, take the missed dose as soon as possible. If the next dose is within 2 days, skip the missed dose and resume the regular schedule. Do not double up. Missing occasional doses may reduce effectiveness but does not require restarting the titration.

How do I know if my dose is too high?

Persistent nausea, vomiting, or diarrhea that does not improve after 2-3 weeks at a given dose level may signal that the dose is too high. Other warning signs include significant fatigue, inability to eat enough to function, or the new dysesthesia signal (tingling and numbness) seen at higher doses in the STEP UP trials. If any of these occur, contact your physician. A dose reduction or slower titration may be needed.

Is semaglutide FDA-approved?

Yes. Semaglutide is FDA-approved for weight loss under the brand name Wegovy (2.4 mg, approved June 2021) and Wegovy HD (7.2 mg, approved March 19, 2026). It is also approved for type 2 diabetes as Ozempic (up to 2.0 mg) and in oral form as Rybelsus. The weight loss indication requires a BMI of 30 or greater, or 27 or greater with at least one weight-related condition.

References

Semaglutide: Full Compound Profile - mechanism of action, pharmacokinetics, and complete research summary
Semaglutide vs Tirzepatide: Head-to-Head Comparison - which GLP-1 drug produces more weight loss
Weight Loss Goals: Complete Research Guide - how peptides fit into the broader weight loss picture
Fat Burning Peptides Explained - appetite suppression vs direct fat burning pathways
Retatrutide Dosage Guide - the triple agonist dosing protocol

Medical Disclaimer

The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any medication or changing your dose. Individual results vary. The editorial team shares published research findings, not medical recommendations. Semaglutide (Wegovy, Wegovy HD, Ozempic) requires a prescription and ongoing medical supervision. Talk to your physician about whether semaglutide is appropriate for your situation.

Free Peptide Weight Loss Guide

Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.